Brendan T. Heiden

Dr. Brendan T. Heiden

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Immunity
Verified
Journal Article
Closed access
NPNatalia B. Pikor
Natalia B. Pikor
JAJillian L. Astarita
Jillian L. Astarita
LSLeslie Summers-Deluca
Leslie Summers-Deluca
GGGeorgina Galicia
Georgina Galicia
JQJoy Qu
Joy Qu
JGJennifer L. Gommerman
Jennifer L. Gommerman

3 May 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
BHBrendan T. Heiden
Brendan T. Heiden
DEDaniel B. Eaton
Daniel B. Eaton
KEKathryn E. Engelhardt
Kathryn E. Engelhardt
SCSu-Hsin Chang
Su-Hsin Chang
YYYan Yan
Yan Yan
VPVarun Puri
Varun Puri
Surgical resection remains the standard treatment for early-stage non–small cell lung cancer (NSCLC) management.1 Patients with NSCLC should receive timely treatment given that delayed surgical treatment holds a theoretical risk for disease progression and therefore poor prognosis.2,3 While several studies4-7 found that delayed surgical treatment is associated with worse outcomes, other studies8-10 found no association. Therefore, whether there is a safe period of time between lung cancer diagnosis and surgical treatment, or treatment in general, remains unclear.

1 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RTRuiyi Tian
Ruiyi Tian
BWBrian Wiley
Brian Wiley
JLJie Liu
Jie Liu
XZXiaoyu Zong
Xiaoyu Zong
BTBuu Truong
Buu Truong
YCYin Cao
Yin Cao
PURPOSE: To prospectively examine the association between clonal hematopoiesis (CH) and subsequent risk of lung cancer. METHODS: Among 200,629 UK Biobank (UKBB) participants with whole-exome sequencing, CH was identified in a nested case-control study of 832 incident lung cancer cases and 3,951 controls (2006-2019) matched on age and year at blood draw, sex, race, and smoking status. A similar nested case-control study (141 cases/652 controls) was conducted among 27,975 participants with whole-exome sequencing in the Mass General Brigham Biobank (MGBB, 2010-2021). In parallel, we compared CH frequency in published data from 5,003 patients with solid tumor (2,279 lung cancer) who had pretreatment blood sequencing performed through Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In UKBB, the presence of CH was associated with increased risk of lung cancer (cases: 12.5% v controls: 8.7%; multivariable-adjusted odds ratio [OR], 1.36; 95% CI, 1.06 to 1.74). The association remained robust after excluding participants with chronic obstructive pulmonary disease. No significant interactions with known risk factors, including polygenic risk score and C-reactive protein, were identified. In MGBB, we observed similar enrichment of CH in lung cancer (cases: 15.6% v controls: 12.7%). The meta-analyzed OR (95% CI) of UKBB and MGBB was 1.35 (1.08 to 1.68) for CH overall and 1.61 (1.19 to 2.18) for variant allele frequencies ≥ 10%. In Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets, CH with a variant allele frequency ≥ 10% was enriched in pretreatment lung cancer compared with other tumors after adjusting for age, sex, and smoking (OR for lung v breast cancer: 1.61; 95% CI, 1.03 to 2.53). CONCLUSION: Independent of known risk factors, CH is associated with increased risk of lung cancer.

29 August 2022 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
BHBrendan T. Heiden
Brendan T. Heiden
DEDaniel B. Eaton
Daniel B. Eaton
SCSu-Hsin Chang
Su-Hsin Chang
YYYan Yan
Yan Yan
MSMartin W. Schoen
Martin W. Schoen
VPVarun Puri
Varun Puri

1 April 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
RRRaju R. Rayavarapu
Raju R. Rayavarapu
BHBrendan T. Heiden
Brendan T. Heiden
NPNicholas Pagani
Nicholas Pagani
MSMelissa M. Shaw
Melissa M. Shaw
SSSydney Shuff
Sydney Shuff
ZSZachary Schafer
Zachary Schafer
The metastasis of cancer cells from the site of the primary tumor to distant sites in the body represents the most deadly manifestation of cancer. In order for metastasis to occur, cancer cells need to evade anoikis, which is defined as apoptosis caused by loss of attachment to extracellular matrix (ECM). Signaling from ErbB2 has previously been linked to the evasion of anoikis in breast cancer cells but the precise molecular mechanisms by which ErbB2 blocks anoikis have yet to be unveiled. In this study, we have identified a novel mechanism by which anoikis is inhibited in ErbB2-expressing cells: multicellular aggregation during ECM-detachment. Our data demonstrate that disruption of aggregation in ErbB2-positive cells is sufficient to induce anoikis and that this anoikis inhibition is a result of aggregation-induced stabilization of EGFR and consequent ERK/MAPK survival signaling. Furthermore, these data suggest that ECM-detached ErbB2-expressing cells may be uniquely susceptible to targeted therapy against EGFR and that this sensitivity could be exploited for specific elimination of ECM-detached cancer cells.

18 November 2021 in Annals of Surgery
Verified
Journal Article
Closed access
BHBrendan T. Heiden
Brendan T. Heiden
DEDaniel B. Jr. Eaton
Daniel B. Jr. Eaton
SCSu-Hsin PhD Chang
Su-Hsin PhD Chang
YYYan Yan
Yan Yan
MSMartin W. Schoen
Martin W. Schoen
VPVarun Md Puri
Varun Md Puri
Objective: To define the relationship between the duration of smoking cessation and postoperative complications for patients with lung cancer undergoing surgical treatment. Background: Smoking increases the risk of postoperative morbidity and mortality in patients with lung cancer undergoing surgical treatment. Although smoking cessation before surgery can mitigate these risks, the ideal duration of preoperative smoking cessation remains unclear. Methods: Using a uniquely compiled Veterans Health Administration dataset, we performed a retrospective cohort study of patients with clinical stage I non-small cell lung cancer undergoing surgical treatment between 2006 and 2016. We characterized the relationship between duration of preoperative smoking cessation and risk of postoperative complications or mortality within 30-days using multivariable restricted cubic spline functions. Results: The study included a total of 9509 patients, of whom 6168 (64.9%) were smoking at the time of lung cancer diagnosis. Among them, only 662 (10.7%) patients stopped smoking prior to surgery. Longer duration between smoking cessation and surgery was associated with lower odds of major complication or mortality (adjusted odds ratio [aOR] for every additional week, 0.919; 95% confidence interval [CI], 0.850-0.993; P = 0.03). Compared to nonsmokers, patients who quit at least 3 weeks before surgery had similar odds of death or major complication (aOR, 1.005; 95% CI, 0.702–1.437; P = 0.98) whereas those who quit within 3 weeks of surgery had significantly higher odds of death or major complication (aOR, 1.698; 95% CI, 1.203–2.396; P = 0.003). Conclusion: Smoking cessation at least 3 weeks prior to the surgical treatment of lung cancer is associated with reduced morbidity and mortality. Providers should aggressively encourage smoking cessation in the preoperative period, since it can disproportionately impact outcomes in early-stage lung cancer.